These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11121565)

  • 1. Optimal control for a stochastic model of cancer chemotherapy.
    Coldman AJ; Murray JM
    Math Biosci; 2000 Dec; 168(2):187-200. PubMed ID: 11121565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: a prospective randomized study.
    Cocconi G; Bisagni G; Bella M; Acito L; Anastasi P; Carpi A; Di Costanzo F; Frassoldati A; Mosconi A; Borrini A; Buzzi P
    Am J Clin Oncol; 1999 Dec; 22(6):593-600. PubMed ID: 10597744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges.
    Lokich JJ; Moore CL; Anderson NR
    Cancer; 1996 Jul; 78(2):294-9. PubMed ID: 8674006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of epirubicin and cyclophosphamide in 2-dose levels and classical CMF protocol in node-positive breast cancer. An adjuvant Phase III trial].
    Ost E; Illiger HJ
    Strahlenther Onkol; 2002 Jan; 178(1):54-5. PubMed ID: 11977396
    [No Abstract]   [Full Text] [Related]  

  • 5. Influence of smoking history on breast cancer prognosis: retrospective study of 240 operable breast cancer patients who received adjuvant cyclophosphamide, doxorubicin, and 5-fluorouracil chemotherapy regimen.
    Aksoy S; Harputluoglu H; Guler N; Altundag K; Hayran M; Tekuzman G; Ozisik Y
    Breast J; 2007; 13(4):431-2. PubMed ID: 17593056
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer.
    Bonadonna G; Zambetti M; Moliterni A; Gianni L; Valagussa P
    J Clin Oncol; 2004 May; 22(9):1614-20. PubMed ID: 15117983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Radiation and concomitant chemotherapy after surgery for breast cancer].
    Calais G
    Cancer Radiother; 2004 Feb; 8(1):39-47. PubMed ID: 15093200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Sequencing of chemotherapy and radiotherapy following breast-preserving treatment of breast carcinoma].
    Sauer R; Martus P
    Strahlenther Onkol; 1996 Sep; 172(9):516-7. PubMed ID: 8928060
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of advanced breast cancer: How much chemotherapy is enough?
    DiPaola RS; Kaufman A; Mikhail MM
    Semin Oncol; 1996 Jun; 23(3):xv-xxii; discussion xxii-xxiv. PubMed ID: 8658211
    [No Abstract]   [Full Text] [Related]  

  • 10. [Adjuvant chemotherapy in older women with breast cancer. CALGB Study (The Cancer and Leukemia Group B Study)].
    Mallmann P; Nitschmann S
    Internist (Berl); 2010 Jul; 51(7):923-4. PubMed ID: 20544172
    [No Abstract]   [Full Text] [Related]  

  • 11. A mathematical model of breast cancer treatment with CMF and doxorubicin.
    Roe-Dale R; Isaacson D; Kupferschmid M
    Bull Math Biol; 2011 Mar; 73(3):585-608. PubMed ID: 20532645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III randomized comparison of postoperative adjuvant chemotherapy with 2-year oral uracil/tegafur versus 6-cycle cyclophosphamide/methotrexate/5-fluorouracil in high-risk node-negative breast cancer patients.
    Watanabe T
    Cancer Chemother Pharmacol; 1998; 42 Suppl():S68-70. PubMed ID: 9750032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgical adjuvant chemotherapy for breast cancer: a comparison of CMF and CAF regimens.
    Babar AM
    J Pak Med Assoc; 1991 Dec; 41(12):293-6. PubMed ID: 1824559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
    Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC
    J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [CMF or CAF combination chemotherapy for breast cancer].
    Ota J
    Gan To Kagaku Ryoho; 1996 Dec; 23(14):1886-90. PubMed ID: 8978791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of costs for infusion versus bolus chemotherapy administration--Part two. Use of charges versus reimbursement for cost basis.
    Lokich JJ; Moore CL; Anderson NR
    Cancer; 1996 Jul; 78(2):300-3. PubMed ID: 8674007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Medical treatment of early breast cancer: chemotherapy].
    Ejlertsen B; Kamby C
    Ugeskr Laeger; 2007 Sep; 169(37):3070-2. PubMed ID: 17877950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes.
    Buzzoni R; Bonadonna G; Valagussa P; Zambetti M
    J Clin Oncol; 1991 Dec; 9(12):2134-40. PubMed ID: 1960555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer.
    De Lena M; Brambilla C; Morabito A; Bonadonna G
    Cancer; 1975 Apr; 35(4):1108-15. PubMed ID: 1116104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive selection and ex vivo expansion of hematopoietic progenitors as autografts for high-dose chemotherapy, potential importance in patients with bone metastases.
    Purdy MH
    Can J Oncol; 1995 Dec; 5 Suppl 1():63-8. PubMed ID: 8853528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.